Genedata, a leading provider of in silico solutions for the pharmaceutical and life sciences industries, today announced a renewed agreement with the National Center for Toxicological Research of the U.S. Food and Drug Administration for the use of Genedata Expressionist® biomarker discovery platform.
Genedata Expressionist is a modular computational platform for biomarker discovery that integrates transcriptomics, proteomics and metabolomics data within a single enterprise software system. With sophisticated high-throughput data processing and automated workflows for quality assessment, as well as statistical analysis and interpretation tools, the platform provides a single point of access for all experimental data, including sample information, raw and pre-processed data, analysis results and documentation with reports.
Weida Tong, director of the Center for Toxicoinformatics at the U.S. Food and Drug Administration (FDA), said, “We have successfully applied Genedata Expressionist in a number of FDA projects, including the Critical Path project and the Liver Toxicity Knowledge Base (LTKB) project. Expressionist is an excellent system for monitoring the quality of gene expression data.”
Othmar Pfannes, CEO of Genedata, added, “We are excited about this collaboration with the FDA. Their use of the Genedata Expressionist system for data quality control validates our approach to omics-data analysis.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.